Patron Partners LLC Boosts Stock Holdings in Stryker Co. (NYSE:SYK)

Patron Partners LLC lifted its stake in Stryker Co. (NYSE:SYK) by 135.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,030 shares of the medical technology company’s stock after buying an additional 1,169 shares during the period. Patron Partners LLC’s holdings in Stryker were worth $731,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Czech National Bank increased its position in Stryker by 8.1% in the third quarter. Czech National Bank now owns 69,843 shares of the medical technology company’s stock worth $25,231,000 after purchasing an additional 5,235 shares during the last quarter. GAMMA Investing LLC grew its holdings in Stryker by 38.7% in the 3rd quarter. GAMMA Investing LLC now owns 2,901 shares of the medical technology company’s stock valued at $1,048,000 after buying an additional 810 shares in the last quarter. Diversified Trust Co grew its stake in shares of Stryker by 5.8% in the third quarter. Diversified Trust Co now owns 14,581 shares of the medical technology company’s stock valued at $5,268,000 after buying an additional 800 shares in the last quarter. Consilio Wealth Advisors LLC acquired a new position in shares of Stryker during the third quarter worth $210,000. Finally, Miracle Mile Advisors LLC boosted its stake in shares of Stryker by 569.2% during the third quarter. Miracle Mile Advisors LLC now owns 5,983 shares of the medical technology company’s stock worth $2,161,000 after buying an additional 5,089 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is owned by corporate insiders.

Stryker Price Performance

SYK stock opened at $390.97 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock has a market capitalization of $149.05 billion, a PE ratio of 50.38, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96. The company’s 50-day moving average is $376.68 and its 200-day moving average is $363.22. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the firm earned $3.46 earnings per share. Equities research analysts expect that Stryker Co. will post 13.5 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st were issued a dividend of $0.84 per share. The ex-dividend date of this dividend was Tuesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s payout ratio is 43.30%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on SYK. JPMorgan Chase & Co. lifted their target price on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. BTIG Research upped their target price on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group boosted their target price on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research report on Thursday, January 30th. Robert W. Baird boosted their price target on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price target on shares of Stryker in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $419.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.